S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$4.17
-0.03 (-0.71%)
(As of 09:30 AM ET)
Today's Range
$4.17
$4.17
50-Day Range
$4.02
$4.86
52-Week Range
$3.45
$6.29
Volume
859 shs
Average Volume
80,388 shs
Market Capitalization
$180.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
66.7% Upside
$7.00 Price Target
Short Interest
Bearish
1.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
0.76mentions of Harvard Bioscience in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Computer And Technology Sector

380th out of 589 stocks

Analytical Instruments Industry

13th out of 28 stocks

HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Q4 2023 Harvard Bioscience Inc Earnings Call
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/27/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
391
Year Founded
1901

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+66.7%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-2.28%

Debt

Sales & Book Value

Annual Sales
$112.25 million
Cash Flow
$0.23 per share
Book Value
$1.71 per share

Miscellaneous

Free Float
40,057,000
Market Cap
$182.28 million
Optionable
Optionable
Beta
1.43

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

HBIO Stock Analysis - Frequently Asked Questions

What is Harvard Bioscience's stock price target for 2024?

0 analysts have issued twelve-month price targets for Harvard Bioscience's shares. Their HBIO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 on January 1st, 2024. Since then, HBIO stock has decreased by 21.5% and is now trading at $4.20.
View the best growth stocks for 2024 here
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a negative net margin of 3.04% and a positive trailing twelve-month return on equity of 2.75%. During the same quarter in the previous year, the business earned $0.01 earnings per share.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include AMH Equity Ltd (5.07%), Vanguard Group Inc. (4.93%), Vanguard Group Inc. (4.93%), Dimensional Fund Advisors LP (4.51%), Granahan Investment Management LLC (4.32%) and Meros Investment Management LP (1.92%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners